Intellectual Property
Idera’s success depends in part on its ability to obtain and maintain proprietary protection for its product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing its proprietary rights.
We use a variety of methods to seek to protect our proprietary position, including filing U.S. and foreign patent applications related to proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.
We have devoted, and continue to devote, a substantial amount of our resources into establishing intellectual property protection for:
- Novel compounds that function as TLR7, 8, or 9 agonists;
- Novel compounds that function as TLR7 and 9 antagonists; and
- Use of our novel compounds to treat and/or prevent a variety of diseases.
Currently Idera holds over 220 issued patents and patent applications world-wide covering its TLR-targeted immune modulation technologies.These patents and patent applications include novel chemical compositions of matter and methods of use for Idera’s immunomodulatory compounds. The following list itemizes Idera's issued and published U.S. patents specific to TLR-targeted technologies.
| › Number | › Title |
| US 7,354,907 | Short immunomodulatory oligonucleotides |
| US 7,329,648 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 7,262,286 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US 7,176,296 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 7,115,579 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 7,105,495 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 6,815,429 | Modulation of Oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 6,476,000 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 6,426,334 | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| US 2008-0152662 A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US 2008-0089883 A1 | Immune Regulatory Oligonucleotide (IRO) Compounds To Modulate Toll-like Receptor Based Immune Response |
| US 2008-0027214 A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes |
| US 2007-0219153 A1 | Immunostimulatory activity of immune modulatory oligonucleotides (IMOtm) containing different lengths of palindromic segments |
| US 2007/0179103 | Immunostimulatory oligonucleotide multimers |
| US 2007/0173469 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US 2007/0105801 | Immunostimulatory Properties of Oligonucleotide-Based Compounds Comprising Modified Immunostimulatory Dinucleotides |
| US 2007/0105800 | Immunostimulatory Properties of Oligonucleotide-Based Compounds Comprising Modified Immunostimulatory Dinucleotides |
| US 2007/0093439 | Short immunomodulatory oligonucleotides |
| US 2007/0072198 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US 2006/0287262 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US 2006/0287261 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US 2006/0217328 | Synergisitic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US 2006/0211641 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US 2006/0142556 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US 2006/0142224 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US 2006/0135454 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US 2006/0105979 | Synergistic inhibition of VEGF and modulation of the immune response |
| US 2006/0094681 | Immunostimulatory oligonucleotide multimers |
| US 2006/0094680 | Immunostimulatory oligonucleotide multimers |
| US 2006/0074040 | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US 2006/0025365 | Immunostimulatory oligonucleotide multimers |
| US 2006/0019919 | Immunostimulatory oligonucleotide multimers |
| US 2006/0019918 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| US 2006/0019909 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US 2006/0014713 | Immunostimulatory oligonucleotide multimers |
| US 2005/0266015 | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide |
| US 2005/0222072 | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
| US 2005/0130918 | Modulation of Immunostimulatory Properties of Small Oligonucleotide-Based Compounds |
| US 2005/0026858 | Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes |
| US 2005/0009773 | Synergistic Treatment of Cancer Using Immunomers in Conjunction with Chemotherapeutic Agents |
| US 2005/0026861 | Stabilized Immunomodulatory Oligonucleotides |
| US 2004/0266710 | Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes |
| US 2004/0266709 | Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes |
| US 2004/0198685 | Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides |
| US 2004/0156825 | Short Immunomodulatory Oligonucleotides |
| US 2002/0151518 | Oligonucleotides Mediated Specific Cytokine Induction and Reduction of Tumor Growth in a Mammal |
